|
Combination Immunotherapy
While active and passive immunotherapies respectively mimic some parts of our immune system, combination immunotherapy most closely resembles the workings of the natural immune system. This type of immunotherapy works on multiple fronts in the battle against cancer. Combination immunotherapy:
| |
• |
Causes a direct and targeted killing of the tumor cells |
|
| |
|
|
|
| |
• |
Activates the immune system to produce a more robust and sustainable anti-tumor response |
|
Combination immunotherapy is multi-targeted because it is aimed at multiple targets on the cancer cell and because it activates multiple cellular components of the immune system to fight cancer.
Multikine: A new class of immunotherapy drugs
Multikine® is the first combination immunotherapy. It is the only immunotherapy that is able to directly affect both the tumor cells themselves and activate a robust anti-tumor immune response.
Multikine® acts against the tumor on multiple fronts. It:
| |
• |
Acts on multiple targets on the cancer cell |
|
| |
|
|
|
| |
• |
Causes a direct and targeted killing of the tumor cells |
|
| |
|
|
|
| |
• |
Activates the immune system to produce a more robust and sustainable anti-tumor response |
|
| |
|
|
|
| |
• |
Renders residual tumor cells susceptible to radiation and/or chemotherapy |
|
Most importantly, Multikine® is not toxic to normal cells. It does not add toxicity to existing therapeutic approaches and may be combined with other anti-cancer treatments. Read more about Multikine
|
